Is Boston going to pass Silicon Valley as the ground zero for the biotechnology industry? Some people think it might.
Because when I think of a drug company, I think of a corporate campus somewhere in New Jersey floating in a square mile bright-green lawn. But that model isn’t working any more. Drug companies are having a hard time coming up with new drugs on their own.
Part of the shift is from chemistry to biology as a way to find drugs. The exciting new drugs are coming out of research into the human genome—often, they’re actually biological molecules. That’s exactly the kind research taking at places like MIT and Harvard’s Longwood Medical campus, across the Charles River.
See on medcitynews.com